Brown, L., Kinsey, E., Kao, C., Healy, P., Armstrong, A., McNamara, M., … Zhang, T. (2019). A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (Vol. 7). BMC.

Brown, Landon, Emily Kinsey, Chester Kao, Patrick Healy, Andrew Armstrong, Megan McNamara, Sundhar Ramalingam, Michael Harrision, Daniel George, and Tian Zhang. “A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab.” In JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 7. BMC, 2019.

Brown L, Kinsey E, Kao C, Healy P, Armstrong A, McNamara M, et al. A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab. In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2019.

Brown, Landon, et al. “A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab.” JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, BMC, 2019.

Brown L, Kinsey E, Kao C, Healy P, Armstrong A, McNamara M, Ramalingam S, Harrision M, George D, Zhang T. A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2019.